‘The Lemtrada scientific trial data demonstrating the treatment's positive impact on relapse prices and disability progression support its potential as a transformational new treatment for relapsing-remitting multiple sclerosis,’ said Norma Deri, M.D., Hosptial Fernandez, Buenos Aires, Argentina pde5 inhibitors . ‘The approval of Lemtrada is very good news for people living with active MS, who may need additional treatment options that may offer better efficacy.’ Lemtrada is backed by a extensive and comprehensive clinical advancement program that involved almost 1,500 patients and 5,400 patient-years of follow-up.
Other essential parameters of medication activity becoming measured in all patients which will also be assessed by the end of the analysis include GROWTH HORMONES and Growth Hormone Binding Protein levels along with a more comprehensive assessment of the safety data. Such additional data is expected to give further precious insight into the safety, mechanism and activity of action of ATL1103 at both dose amounts in this patient population. Chief Investigator for this scholarly study, Dr Peter Trainer, Professor of Endocrinology, The Christie NHS Foundation Trust, UK, stated: ‘The reduction in sIGF-I observed at the 400 mg dose in this small number of patients is usually most encouraging and facilitates the continuing recruitment of sufferers into the study and in addition shows the potential to explore higher dosages and various dosing schedules in long term clinical trials to optimize ATL1103 usage.’ Mark Gemstone, Managing Director and CEO of Antisense Therapeutics stated: ‘These positive interim outcomes provide us with important indicative data on the efficacy and safety of ATL1103 in treating acromegaly sufferers.